血液系统恶性肿瘤单倍体干细胞移植后的长期结局
该回顾性研究评估了2009年2月至2019年3月间首次接受单倍体干细胞移植的335例血液系统恶性肿瘤患者的长期结局,中位年龄48岁。移植后2年无病生存的142例患者4年无进展生存率和总生存率分别为94%和96%,晚期复发罕见,年龄≥55岁是唯一预测不良长期结局的因素。
要点
- 移植后2年无病生存者4年无进展生存率和总生存率分别为94%和96%。
- 长期生存组4年累积复发率和非复发死亡率分别为2.9%和3.3%。
- 多因素分析中年龄≥55岁是唯一预测较差无进展生存率和总生存率的因素。
核心结论
- 对于接受基于移植后环磷酰胺的移植物抗宿主病预防方案的单倍体干细胞移植患者,移植后2年无病生存者长期生存率极好,晚期复发罕见,年龄是唯一预测长期结局的因素。
研究设计与样本
- 回顾性评估2009年2月至2019年3月间首次接受单倍体干细胞移植的335例血液系统恶性肿瘤患者,中位年龄48岁(范围18-72岁)。
- 长期生存者定义为移植后2年存活且无病。
主要发现
- 全部研究患者4年无进展生存率和总生存率分别为42%和47%。
- 长期生存者组(n=142)中位随访52个月,4年无进展生存率和总生存率分别为94%和96%。
- 长期生存者组4年累积复发率和非复发死亡率分别为2.9%和3.3%。
- 多因素分析中年龄≥55岁是较差无进展生存率的唯一预测因素(HR 3.41;95%CI 1.21-9.60;P=0.020)和较差总生存率的唯一预测因素(HR 3.31;95%CI 1.08-10.18;P=0.037)。
- 长期生存者组13例(9%)死亡,其中仅2例死于复发疾病;继发性原发性恶性肿瘤是非复发死亡最常见原因(n=4),其次为感染(n=2)。
关键数值与推荐
- 长期生存者组4年无进展生存率94%,总生存率96%。
- 长期生存者组4年累积复发率2.9%,非复发死亡率3.3%。
- 年龄≥55岁与较差无进展生存率相关(HR 3.41;95%CI 1.21-9.60;P=0.020)和较差总生存率相关(HR 3.31;95%CI 1.08-10.18;P=0.037)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The introduction of posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis lead to significant improvements in haploidentical stem cell transplantation (haplo-SCT) outcomes over the past decade. We retrospectively assessed long-term outcomes of patients who had their first haplo-SCT between February 2009 and March 2019. Long-term survivors were defined as patients who were alive and disease-free at 2 years after transplant. Three hundred thirty-five patients with a median age of 48 years (range, 18-72) were identified. Of these, 142 patients were disease-free and alive at 2 years after transplant. The 4-year progression-free survival (PFS) and overall survival (OS) for all study patients were 42% and 47%, respectively. With a median follow-up of 52 months for the long-term survivor group, the 4-year PFS and OS were 94% and 96%, respectively. The 4-year cumulative incidence of relapse and non-relapse mortality (NRM) were 2.9% and 3.3%, respectively. Age ≥55 years was the only predictive factor in multivariate analysis for inferior PFS (hazard ratio [HR], 3.41; 95% confidence interval [CI], 1.21-9.60; P = .020) and OS (HR, 3.31; 95% CI, 1.08-10.18; P = .037). Thirteen patients (9%) died in the long-term survivor group, only 2 of whom died of relapsed disease. Secondary primary malignancy was the most frequent cause of NRM (n = 4), followed by infection (n = 2). For haplo-SCT with PTCy-based GVHD prophylaxis, our findings suggest an excellent long-term survival for patients who were disease-free and alive at 2 years after transplant. Late relapses were rare, and age was the only predictive factor for long-term outcomes.
引用
- Saengboon S, Ciurea S, Popat U, et al. Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies. Blood Adv. 2024. PMID: 38607399. doi:10.1182/bloodadvances.2023010625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。